WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on ...

Bellerophon Therapeutics BLPH was up 18.04% on Sep 27 after the company announced the FDA’s acceptance of its proposal to reduce the size of its ongoing phase III REBUILD study. The study is ...

Though its eponym in Greek mythology was able to successfully defeat the fire-breathing chimera, Bellerophon Therapeutics’ story is closing out on a much less victorious note. The New Jersey ...

TARRYTOWN, N.Y. — As post-lunch drowsiness settled on an auditorium full of leaders from the drug development industry, Peter Fernandes, CEO of Bellerophon Therapeutics, seized the presentation ...